Your browser doesn't support javascript.
loading
Activation of pregnane X receptor induces atherogenic lipids and PCSK9 by a SREBP2-mediated mechanism.
Karpale, Mikko; Käräjämäki, Aki Juhani; Kummu, Outi; Gylling, Helena; Hyötyläinen, Tuulia; Oresic, Matej; Tolonen, Ari; Hautajärvi, Heidi; Savolainen, Markku J; Ala-Korpela, Mika; Hukkanen, Janne; Hakkola, Jukka.
Affiliation
  • Karpale M; Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
  • Käräjämäki AJ; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Kummu O; Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Gylling H; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Hyötyläinen T; Department of gastroenterology, Clinics of Internal Medicine, Vaasa Central Hospital, Vaasa, Finland.
  • Oresic M; Abdominal Center, Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.
  • Tolonen A; Research Unit of Biomedicine, University of Oulu, Oulu, Finland.
  • Hautajärvi H; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Savolainen MJ; Biocenter Oulu, University of Oulu, Oulu, Finland.
  • Ala-Korpela M; Heart and Lung Center, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Hukkanen J; School of Science and Technology, Örebro University, Örebro, Sweden.
  • Hakkola J; School of Medical Sciences, Örebro University, Örebro, Sweden.
Br J Pharmacol ; 178(12): 2461-2481, 2021 06.
Article in En | MEDLINE | ID: mdl-33687065
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Proprotein Convertase 9 Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Br J Pharmacol Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Proprotein Convertase 9 Type of study: Clinical_trials Limits: Animals / Humans Language: En Journal: Br J Pharmacol Year: 2021 Document type: Article